ecancermedicalscience

Research

HPV-DNA testing for cervical cancer precursors: from evidence to clinical practice

18 Jun 2012
M Origoni, P Cristoforoni, S Costa, L Mariani, P Scirpa, A Lorincz, M Sideri

The large amount of literature published over the last two decades on human papillomavirus (HPV)-DNA testing has definitely demonstrated the association between high-risk viral genotypes (hrHPV) and cervical cancer. Moreover, hrHPV-DNA testing has shown excellent performance in several clinical applications, from screening settings to the follow-up of treated patients, compared to conventional cytology or colposcopy options. On the other hand, when a huge number of reports are published on the same subject in a relatively short period of time, with many variations in settings, study designs and applications, the result is often confusion and decreased comprehension by readers. In daily office practice, several different situations (in symptomatic or asymptomatic women) can be positively managed by the correct use of hrHPV-DNA testing. Validated hrHPV-DNA testing and, specifically, the HC2® assay, due to its excellent sensitivity and negative predictive value together with optimal reproducibility, currently represent a powerful tool in the clinician’s hands to optimally manage several situations related to HPV infection and the potential development of cervical cancer.

Related Articles

Jemma Arakelyan, Alisa Movsisyan, Lilit Sargsyan, Armine Chopikyan, Diana Andreasyan, Arevik Torosyan, Ruzanna Papyan, Hovhannes Vardevanyan, Samvel Bardakhchyan, Artashes Tadevosyan, Gevorg Tamamyan, Armen Tananyan, Samvel Danielyan, Dickran Kazandjian
Deepthi Valiyaveettil, Swapna Jilla, Jonnalagadda Mohan Krishna, Raja Kollu, Chandrasekhar Patil, Ranadheer Gupta
Renata Colombo Bonadio, Ana Paula Messias, Otavio Augusto Moreira, Letícia Vecchi Leis, Bruna Zanin Orsi, Laura Testa, Maria del Pilar Estevez-Diz